Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New depression drug enters Mid-Stage testing

NCT ID NCT06842992

Summary

This study tested a new drug called NH102 to see if it helps reduce symptoms of major depression. It involved 243 adults with depression who took either NH102 at different doses, an existing drug (duloxetine), or a placebo for 6 weeks. The main goal was to see how well NH102 worked compared to the other options and to check its safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Shanghai Mental Health Center

    Shanghai, China

Conditions

Explore the condition pages connected to this study.